Hospira Upgraded to Buy by Jefferson Research (HSP)
Hospira (NYSE:HSP) was upgraded by Jefferson Research from a “hold” rating to a “buy” rating in a research note issued on Friday, AnalystRatings.NET reports.
Hospira (NYSE:HSP) traded down 0.82% during mid-day trading on Friday, hitting $43.75. 382,025 shares of the company’s stock traded hands. Hospira has a 52 week low of $28.71 and a 52 week high of $45.24. The stock has a 50-day moving average of $42.83 and a 200-day moving average of $40.80. The company’s market cap is $7.258 billion.
Hospira (NYSE:HSP) last announced its earnings results on Wednesday, February 12th. The company reported $0.51 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.50 by $0.01. The company had revenue of $1.10 billion for the quarter, compared to the consensus estimate of $1.06 billion. During the same quarter last year, the company posted $0.55 earnings per share. Hospira’s revenue was down 1.3% compared to the same quarter last year. On average, analysts predict that Hospira will post $2.13 earnings per share for the current fiscal year.
Other equities research analysts have also recently issued reports about the stock. Analysts at Guggenheim raised their price target on shares of Hospira from $49.00 to $53.00 in a research note on Thursday. Separately, analysts at Leerink Swann raised their price target on shares of Hospira from $45.00 to $46.00 in a research note on Thursday. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the company. Hospira presently has a consensus rating of “Hold” and a consensus target price of $41.00.
Hospira, Inc (NYSE:HSP) is a provider of injectable drugs and infusion technologies.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.